Clinical Trial Update: Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism [Phase 4]

View source ↗

Summary

A Phase 4 study compares bleeding risk between rivaroxaban and apixaban for treatment of acute venous thromboembolism.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• Eliquis (apixaban)
• Xarelto (rivaroxaban)

Snippet

Sponsor: Ottawa Hospital Research Institute | Conditions: Venous Thromboembolism | Phase 4 | Status: COMPLETED